- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Hamilton on HRQOL Differences With Gilteritinib Vs Placebo in Post-Transplant FLT3-ITD+ AML
February 23rd 2024, 10:18pm
Transplantation and Cellular Therapy Meetings
Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.
Dr Lee on 3-Year Follow-Up Data From the ROCKstar Trial of Belumosudil in cGVHD
February 23rd 2024, 8:49pm
Transplantation and Cellular Therapy Meetings
Stephanie Lee, MD, MPH, discusses 3-year follow-up data from the phase 3 ROCKstar Study of belumosudil in cGVHD.
Immune Engager Therapies Demonstrate Promise Following Relapse on Ide-Cel in Multiple Myeloma
February 23rd 2024, 8:40pm
Transplantation and Cellular Therapy Meetings
Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.
Liso-Cel Demonstrates Durable Efficacy in Relapsed/Refractory CLL/SLL
February 23rd 2024, 7:50pm
Transplantation and Cellular Therapy Meetings
Lisocabtagene maraleucel elicited durable responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Concomitant Azoles Does Not Affect Clinical Outcomes With Ruxolitinib in Acute GVHD
February 23rd 2024, 7:15pm
Transplantation and Cellular Therapy Meetings
Concomitant azoles did not negatively affect efficacy with ruxolitinib or best available therapy in patients with acute graft-versus-host disease.
Cilta-Cel Sustains MRD-Negative Responses in Previously Treated Multiple Myeloma
February 23rd 2024, 6:43pm
Transplantation and Cellular Therapy Meetings
Cilta-cel continues to elicit deep and durable responses in patients with early relapsed multiple myeloma, including those refractory to lenalidomide.
Ruxolitinib Plus Belumosudil Boosts Responses in Chronic GVHD
February 23rd 2024, 5:24pm
Transplantation and Cellular Therapy Meetings
Ruxolitinib and belumosudil demonstrated a beneficial ORR, indicating synergistic effects in targeting multiple inflammatory pathways in chronic GVHD.
Ruxolitinib Cream Is Tolerable and Effective in Cutaneous GVHD
February 23rd 2024, 5:15pm
Transplantation and Cellular Therapy Meetings
A cream formulation of ruxolitinib was deemed safe and effective compared with placebo in patients with cutaneous graft-versus-host disease.
Acalabrutinib/Axi-Cel Generates Preliminary Responses in Relapsed/Refractory B-Cell Lymphoma
February 23rd 2024, 2:35am
Transplantation and Cellular Therapy Meetings
Early data seen with acalabrutinib plus axi-cel indicate the combination’s feasibility as bridging therapy in relapsed/refractory B-cell lymphoma.
CNS Remission Achieved With Brexu-Cel in Relapsed/Refractory B-ALL
February 22nd 2024, 4:21pm
Transplantation and Cellular Therapy Meetings
Brexu-cel showed efficacy in eliciting both CNS and systemic responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Liso-Cel Proves Active Across High-Risk MCL Subgroups
February 22nd 2024, 3:45pm
Transplantation and Cellular Therapy Meetings
Liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features.
Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization
February 7th 2024, 7:00pm
PER® Winter Lung Cancer Conference
Identifying biomarkers and the mechanism of action of antibody-drug conjugates may optimize benefits with these agents in non–small cell lung cancer.
Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?
February 7th 2024, 7:00pm
PER® Winter Lung Cancer Conference
Survival outcomes following curative resection in resectable NSCLC have been poor and, until recently, the main tool oncologists had at their disposal was neoadjuvant or adjuvant chemotherapy.
EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management
February 7th 2024, 6:00pm
PER® Winter Lung Cancer Conference
Balazs Halmos, MD, discusses the FLAURA2 and MARIPOSA trials of EGFR TKIs plus chemotherapy in EGFR-mutated non–small cell lung cancer.
Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment
February 6th 2024, 11:18pm
PER® Winter Lung Cancer Conference
Coral Olazagasti, MD, discusses her participation in a case-based discussion at the 21st Annual Winter Lung Cancer Conference®.
Dr Rosner on Personalizing Approaches to Perioperative Therapy in NSCLC
February 6th 2024, 11:18pm
PER® Winter Lung Cancer Conference
Samuel Rosner, MD, discusses ongoing efforts to individualize the use of perioperative/neoadjuvant therapy in early-stage NSCLC.
EGFR-Targeted TKIs Continue to Have Outsized Impact in NSCLC
February 6th 2024, 9:40pm
PER® Winter Lung Cancer Conference
Thomas J. Lynch Jr, MD, details how treatments are evolving for patients with EGFR-mutated advanced non–small cell lung cancer.
Diving Into Adjuvant Approaches in Early-Stage Resectable NSCLC: PD-L1 Expression and Genomic Considerations
February 6th 2024, 9:27pm
PER® Winter Lung Cancer Conference
Corey J. Langer, MD, FACP, discusses findings from the IMpower010 and KEYNOTE-091 studies, which examined immunotherapy in NSCLC.
Dr Halmos on Treatment Strategies For EGFR-Mutant NSCLC
February 4th 2024, 7:40pm
PER® Winter Lung Cancer Conference
Balazs Halmos, MD, discusses treatment strategies for patients with EGFR-mutant non–small cell lung cancer.
Dr Curran on Developing Strategies for Stage III NSCLC Management
February 4th 2024, 5:50pm
PER® Winter Lung Cancer Conference
Wally Curran, MD, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer.